SANDUPHQ

Sandu Pharmaceuticals financials

Market cap
₹37 Cr

Quarterly results

Q4 FY25: revenue down 9.8%, net profit down 44.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25
Revenue18 17 17 16 17 −3%18 +7%18 +5%14 −10%
EBITDA0 1 1 1 0 +17%1 +11%1 +96%0 −26%
Net profit0 1 0 1 0 +55%1 −9%1 +167%0 −44%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −21.8% 1Y

₹30.0₹35.0₹40.0₹45.0₹50.0Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹48.41 on 9 Sept 2025 → ₹37.88. High ₹48.95 (16 Sept 2025), low ₹30.52 (30 Mar 2026).

Financials, as filed

Revenue grew 1.4% a year over 2 years, FY23 to FY25. Operating margin held at 4.1%.

Year endingFY23FY24FY25
Revenue₹65 Cr₹67 Cr₹67 Cr
Operating profit₹2 Cr₹2 Cr₹3 Cr
Operating margin3.8%3.4%4.1%
Interest₹0 Cr₹0 Cr₹0 Cr
Depreciation₹1 Cr₹1 Cr₹1 Cr
Net profit₹2 Cr₹1 Cr₹2 Cr
Net margin2.3%2.2%2.3%
Cash from operations₹0 Cr₹1 Cr₹1 Cr
Free cash flow₹-1 Cr₹-1 Cr₹0 Cr
ROCE6.0%5.4%5.5%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY22FY23FY24FY25
Equity capital₹9 Cr₹10 Cr₹10 Cr₹10 Cr
Reserves₹28 Cr₹30 Cr₹31 Cr₹32 Cr
Borrowings₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Other liabilities₹13 Cr₹15 Cr₹12 Cr₹14 Cr
Total liabilities₹49 Cr₹54 Cr₹52 Cr₹56 Cr
Fixed assets₹16 Cr₹17 Cr₹18 Cr₹18 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Investments₹9 Cr₹10 Cr₹10 Cr₹11 Cr
Other assets₹24 Cr₹27 Cr₹24 Cr₹26 Cr
Total assets₹49 Cr₹54 Cr₹52 Cr₹56 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, promoters trimmed −5.12 pp while the public added +5.12 pp.

Promoters
37.8%
DIIs
0.0%
Public
62.2%

Since Jun 2025

  • Promoters −5.12 pp
  • Public +5.12 pp
  • DIIs 0.00 pp

How it drifted, 12 quarters

Over this window promoters fell from 42.9% to 37.8% — −5.1 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 42.9%, DIIs 0.0%, Public 57.1%.Dec '23: Promoters 42.9%, DIIs 0.0%, Public 57.1%.Mar '24: Promoters 42.9%, DIIs 0.0%, Public 57.1%.Jun '24: Promoters 42.9%, DIIs 0.0%, Public 57.1%.Sep '24: Promoters 42.9%, DIIs 0.0%, Public 57.1%.Dec '24: Promoters 42.9%, DIIs 0.0%, Public 57.1%.Mar '25: Promoters 42.9%, DIIs 0.0%, Public 57.1%.Jun '25: Promoters 42.9%, DIIs 0.0%, Public 57.1%.Sep '25: Promoters 42.9%, DIIs 0.0%, Public 57.1%.Dec '25: Promoters 37.8%, DIIs 0.0%, Public 62.2%.Mar '26: Promoters 37.8%, DIIs 0.0%, Public 62.2%.Jun '26: Promoters 37.8%, DIIs 0.0%, Public 62.2%.

Who was buying across the market this quarter →

Who is on the register

Named in the Jun 2026 filing

Every holder of Sandu Pharmaceuticals Ltd. above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Umesh Bhaskar Sandu 14.37%unchanged
Shashank Bhaskar Sandu 14.17%unchanged
Jayshree Bhaskar Sandu 7.63%unchanged
Sanmark Realty And Finance Private Limited 5.63%unchanged
Akshath Finvest And Properties Private Limited 5.12%unchanged
Neelamber Leasing And Finvest Private Limited 4.71%unchanged
Tanvi Jignesh Mehta 4.61%unchanged
Sanbro Marketing Services Pvt Ltd 2.59%unchanged
Noumura Realty And Constructions Private Limited 2.27%unchanged
Phybrichem Engineers Private Limited 1.61%unchanged
Hitesh Kuvelkar 1.26%unchanged
Geeta U Sandu 0.88%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse Sandu Pharmaceuticals Ltd.

Guides on how to read this kind of business and the numbers that matter.